CLINICAL TRIALS PROFILE FOR MITOMYCIN

505(b)(2) Clinical Trials for MITOMYCIN

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT00974818 ↗	Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients	Terminated	New York Presbyterian Hospital	Phase 3	2009-09-01	The purpose of this study is to compare the bladder cancer treatments, Mitomycin C (MMC) and Bacillus Calmette Guerin (BCG), to find out which is better. In this study, the patient will get either the Mitomycin C (MMC) or the Bacillus Calmette Guerin (BCG). They will not get both. The patient had a Transurethral Resection (TUR) or an in office cystoscopy to make the diagnosis of bladder cancer. A biopsy was done and removed any tumors the doctor saw. Even after the doctor removes the tumors, the cancer can return. In this case, the doctor will put medicine into the bladder to destroy cancer cell. This is called intravesical therapy. The two most commonly used drugs for this purpose are MMC and BCG. Both drugs have been studied for many years. They both show good results when compared to other treatments. They have not been studied using the schedule that will be used in the study. The doctor does not know if these two drugs are equally effective in treating the cancer and preventing recurrence. BCG has been studied more often than MMC. The studies have shown that a long schedule of BCG is better than a short schedule of MMC. They have also shown that the side effects of BCG are more intense than with MMC. A recent study showed that a new dose of MMC is better than the old standard dose. Since the side effects of MMC occur less often, it is important to learn whether the two drugs are equally effective. That could help us decide between the treatments. In this study, the doctor will compare MMC and BCG when given for the same amount of time. The doctor hopes the study will tell us which drug is more effective in preventing the return of the cancer.
New Dosage	NCT00974818 ↗	Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients	Terminated	Weill Medical College of Cornell University	Phase 3	2009-09-01	The purpose of this study is to compare the bladder cancer treatments, Mitomycin C (MMC) and Bacillus Calmette Guerin (BCG), to find out which is better. In this study, the patient will get either the Mitomycin C (MMC) or the Bacillus Calmette Guerin (BCG). They will not get both. The patient had a Transurethral Resection (TUR) or an in office cystoscopy to make the diagnosis of bladder cancer. A biopsy was done and removed any tumors the doctor saw. Even after the doctor removes the tumors, the cancer can return. In this case, the doctor will put medicine into the bladder to destroy cancer cell. This is called intravesical therapy. The two most commonly used drugs for this purpose are MMC and BCG. Both drugs have been studied for many years. They both show good results when compared to other treatments. They have not been studied using the schedule that will be used in the study. The doctor does not know if these two drugs are equally effective in treating the cancer and preventing recurrence. BCG has been studied more often than MMC. The studies have shown that a long schedule of BCG is better than a short schedule of MMC. They have also shown that the side effects of BCG are more intense than with MMC. A recent study showed that a new dose of MMC is better than the old standard dose. Since the side effects of MMC occur less often, it is important to learn whether the two drugs are equally effective. That could help us decide between the treatments. In this study, the doctor will compare MMC and BCG when given for the same amount of time. The doctor hopes the study will tell us which drug is more effective in preventing the return of the cancer.
New Dosage	NCT00974818 ↗	Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients	Terminated	Memorial Sloan Kettering Cancer Center	Phase 3	2009-09-01	The purpose of this study is to compare the bladder cancer treatments, Mitomycin C (MMC) and Bacillus Calmette Guerin (BCG), to find out which is better. In this study, the patient will get either the Mitomycin C (MMC) or the Bacillus Calmette Guerin (BCG). They will not get both. The patient had a Transurethral Resection (TUR) or an in office cystoscopy to make the diagnosis of bladder cancer. A biopsy was done and removed any tumors the doctor saw. Even after the doctor removes the tumors, the cancer can return. In this case, the doctor will put medicine into the bladder to destroy cancer cell. This is called intravesical therapy. The two most commonly used drugs for this purpose are MMC and BCG. Both drugs have been studied for many years. They both show good results when compared to other treatments. They have not been studied using the schedule that will be used in the study. The doctor does not know if these two drugs are equally effective in treating the cancer and preventing recurrence. BCG has been studied more often than MMC. The studies have shown that a long schedule of BCG is better than a short schedule of MMC. They have also shown that the side effects of BCG are more intense than with MMC. A recent study showed that a new dose of MMC is better than the old standard dose. Since the side effects of MMC occur less often, it is important to learn whether the two drugs are equally effective. That could help us decide between the treatments. In this study, the doctor will compare MMC and BCG when given for the same amount of time. The doctor hopes the study will tell us which drug is more effective in preventing the return of the cancer.
New Formulation	NCT03268499 ↗	TACE Emulsion Versus Suspension	Recruiting	Chinese University of Hong Kong	Phase 2	2016-09-01	The aim of the study was to evaluate the safety and efficacy of using the new formulation (Lipiodol-cisplatin suspension) for TACE in the treatment of HCC as compared to the conventional formulation (Lipiodol-cisplatin emulsion). This is a prospective, parallel-group, open-label randomized, phase II study that is conducted in accordance to the Declaration of Helsinki and international standards of Good Clinical Practice, and approved by the institutional review board. Eligible patients were randomized into either a treatment arm of Lipiodol-cisplatin suspension or a control arm of Lipiodol-cisplatin emulsion with a 1:1 ratio.

All Clinical Trials for MITOMYCIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002490 ↗	Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer	Completed	Medical Research Council	Phase 3	1991-09-01	RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not known whether receiving either radiation therapy, chemotherapy, or observation is more effective for cancer of the bladder. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy, chemotherapy, or observation following tumor surgery in treating patients who have bladder cancer.
NCT00002507 ↗	Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer	Completed	Yale University	Phase 3	1992-11-01	RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combining mitomycin or porfiromycin with radiation therapy is more effective in treating patients with head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus either mitomycin or porfiromycin in treating patients with head and neck cancer.
NCT00002993 ↗	Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus	Terminated	National Cancer Institute (NCI)	Phase 2	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with mitomycin, doxorubicin, and cisplatin in treating patients with recurrent or advanced cancer of the uterus.
NCT00002993 ↗	Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus	Terminated	Gynecologic Oncology Group	Phase 2	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with mitomycin, doxorubicin, and cisplatin in treating patients with recurrent or advanced cancer of the uterus.

Clinical Trial Conditions for MITOMYCIN

Condition Name

Condition Name for MITOMYCIN
Intervention	Trials
Bladder Cancer	29
Glaucoma	19
Colorectal Cancer	12
Anal Cancer	10

Condition MeSH

Condition MeSH for MITOMYCIN
Intervention	Trials
Urinary Bladder Neoplasms	53
Carcinoma	44
Glaucoma	29
Anus Neoplasms	23

Clinical Trial Locations for MITOMYCIN

Trials by Country

Trials by Country for MITOMYCIN
Location	Trials
United States	514
United Kingdom	60
China	24
Spain	20
Italy	15

Trials by US State

Trials by US State for MITOMYCIN
Location	Trials
California	31
New York	26
Texas	25
Pennsylvania	25
Maryland	25

Clinical Trial Progress for MITOMYCIN

Clinical Trial Phase

Clinical Trial Phase for MITOMYCIN
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	10
PHASE2	8

Clinical Trial Status

Clinical Trial Status for MITOMYCIN
Clinical Trial Phase	Trials
Completed	104
Unknown status	45
Recruiting	41

Clinical Trial Sponsors for MITOMYCIN

Sponsor Name

Sponsor Name for MITOMYCIN
Sponsor	Trials
National Cancer Institute (NCI)	40
UroGen Pharma Ltd.	7
Medical Research Council	5

Sponsor Type

Sponsor Type for MITOMYCIN
Sponsor	Trials
Other	346
Industry	49
NIH	42

MITOMYCIN Market Analysis and Financial Projection

Last updated: April 27, 2026

Mitomycin: Clinical Trials Update, Market Analysis and 10-Year Projection

What is Mitomycin and how is it used clinically?

Mitomycin is an older anticancer antibiotic (mitosane class) used primarily as an antineoplastic agent in oncology and as a topical/adjunct therapy in select procedures. Commercial and clinical positioning remains anchored in established indications and hospital use rather than broad, late-stage pipeline expansion.

Clinical practice patterns that drive ongoing demand:

• Solid tumor chemotherapy: systemic use historically in indications including gastric, pancreatic, and head-and-neck cancers in various regimens.
• Bladder cancer / intravesical use: mitomycin is used intravesically after transurethral resection for non-muscle-invasive bladder cancer (NMIBC) risk categories, where it competes with BCG and other chemotherapeutics.
• Local procedural oncology: mitomycin is used in select local therapies (country- and product-dependent).

Regulatory and labeling scope varies materially by jurisdiction, formulation, and route of administration (systemic vs intravesical vs other local use).

---

What do the latest clinical trial trends show for Mitomycin?

Mitomycin’s clinical trial footprint is smaller than for newer DNA-targeting agents, but the program mix is steady: oncology studies and device/procedure-adjacent protocols continue, with periodic incremental studies (formulation, dosing, schedules, and combination strategies).

Recent and ongoing trial activity themes (high level)

• NMIBC / intravesical therapy: trials track recurrence control and progression endpoints; studies often compare dosing schedules or combinations rather than launching novel mechanisms.
• Combination chemotherapy and salvage regimens: studies evaluate mitomycin’s role with contemporary backbones.
• Re-formulation and delivery approaches: ongoing work targets administration logistics and tolerability.

Proof points from clinical trial registries

• A structured query across major registries indicates ongoing activity, but the count and novelty level are lower than for newer compounds. The trial set is dominated by oncology and urology-related protocols. (Source: ClinicalTrials.gov query results and listings). [1]

Trial pipeline maturity

• Mitomycin functions like a mature, re-used oncology cytotoxic rather than a compound with a large, new mechanism-led pipeline.
• Expect continuation of studies that refine existing use cases, with limited probability of a single “transformational” pivotal trial that remaps market share at global scale.

---

What is the current market structure for Mitomycin?

Mitomycin market demand is shaped by:

• Product format: powder for injection and intravesical formulations.
• Hospital procurement dynamics: oncology and urology centers drive volume; usage correlates with cancer incidence and NMIBC treatment pathways.
• Pricing pressure and supply concentration: as an older cytotoxic, pricing tends to face periodic downward pressure where multiple suppliers exist, and spikes during supply constraints.

Key market demand drivers

1. NMIBC incidence and recurrence burden
   NMIBC generates repeated procedures and maintenance therapy needs, which can sustain institutional demand.
2. Clinical preference for intravesical chemotherapy
   Where BCG is limited by availability, tolerance, or guideline selection, mitomycin can remain an option.
3. Combination chemotherapy cycles
   Systemic use depends on regimen selection and patient-level factors.

Competitive set

• Other intravesical agents for NMIBC (where available by jurisdiction): gemcitabine, docetaxel (some regions), epirubicin.
• Systemic cytotoxics for solid tumors: mitomycin competes indirectly via regimen choice.

---

How big is the Mitomycin opportunity and what does it depend on?

A robust market forecast for “mitomycin” requires disaggregation by route (systemic vs intravesical) and by geography because guidelines and access differ. Based on current commercial reality, the addressable market is primarily oncology hospital drug spend with a meaningful urology subset.

Given the lack of a single unified global dataset in public sources that cleanly aggregates all routes and branded/generic stock-keeping units into one number, projections are best approached as scenario-based volume and unit-price modeling anchored to institutional use patterns.

Modeling logic used for projection

• Volume: NMIBC treatment prevalence times dosing frequency (intravesical) plus systemic usage in solid tumors where mitomycin remains in regimens.
• Price: declines driven by genericization, tempered by supply constraints and procurement contracts.
• Substitution risk: competitive intravesical agents can displace mitomycin where efficacy, tolerability, and payer preferences align.
• Regulatory stability: no major mechanism change, so growth is driven by utilization, not by label expansion.

---

Market outlook: 10-year projection (2026–2035)

Base case assumes:

• Stable or modest growth in institutional utilization driven by cancer incidence.
• Ongoing price pressure consistent with older cytotoxic market behavior.
• Incremental substitution risk in NMIBC where alternatives gain penetration but not at a level that eliminates mitomycin entirely.

Projected performance indicators (global, directional)

• Revenue: low-to-mid single digit CAGR in nominal terms, with margin compression if unit pricing continues to decline.
• Volume: modest growth, supported by repeat intravesical treatment cycles and stable systemic niche use.

Because mitomycin is mature and generics dominate many markets, the highest sensitivity is to:

• NMIBC guideline adoption shifts
• BCG availability constraints
• Supply continuity (manufacturing outages create short-term spikes, but not durable growth)

Investment interpretation

• Mitomycin is better treated as a cash-generating mature asset (or cost-efficient generic supplier play) than as a growth engine for breakthrough R&D.
• Upside is constrained unless new formulation wins strong guideline positioning or a large geographic access gap opens.

---

Where are the key risks and upside levers?

Primary risks

• Intravesical substitution by alternative agents with growing guideline support in many settings.
• Procurement price competition as more generic versions compete.
• Supply chain fragility typical of sterile oncology manufacturing inputs.

Upside levers

• BCG shortage periods that increase chemotherapy use.
• Guideline inertia in regions where mitomycin remains a default intravesical comparator or maintenance approach.
• Formulation improvements that reduce administration time or improve tolerability, supporting institutional preference.

---

What is the regulatory and patent reality that matters commercially?

Mitomycin’s core molecule is long off-patent in most jurisdictions. Commercial differentiation tends to come from:

• formulation and route-of-administration
• sterility assurance process
• packaging and intravesical administration readiness
• quality systems and supply reliability

As a result, the dominant commercial lever is not new IP, but manufacturing scale, regulatory compliance execution, and contract procurement.

---

Key Takeaways

• Mitomycin remains a mature oncology cytotoxic with ongoing clinical trial activity concentrated in urology and combination or schedule optimization studies.
• Market demand is anchored in institutional oncology use, especially intravesical therapy for NMIBC, with continued sensitivity to BCG availability and intravesical substitution.
• A 2026–2035 forecast is best treated as modest nominal growth with price pressure, supported by volume stability and NMIBC recurrence cycles rather than by mechanism-changing label expansion.
• Commercial strategy should prioritize supply reliability, formulation competitiveness, and payer/institution pathway alignment, not new mechanism-led R&D.

---

FAQs

1) Does Mitomycin have a large late-stage development pipeline?
No. Trial activity exists but is dominated by incremental studies, schedule refinements, and combination approaches rather than large mechanism-shifting pivotal programs. [1]

2) What drives Mitomycin demand most?
Intravesical use in NMIBC and sustained institutional chemotherapy utilization in oncology regimens, both tied to recurrence cycles and clinical pathway selection. [1]

3) Which competitive products most pressure Mitomycin?
Intravesical chemotherapies and newer agents used in NMIBC treatment pathways where guidelines and payer preferences favor alternatives. [1]

4) How does generic competition affect Mitomycin pricing?
It typically drives downward unit pricing over time, shifting profitability toward procurement scale, contracting strength, and supply continuity.

5) What is the biggest commercial swing factor for the next decade?
BCG availability and intravesical treatment pathway shifts, which can increase or reduce mitomycin utilization without changing the drug itself. [1]

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. Mitomycin search results and registered studies. https://clinicaltrials.gov/